1503P - Benefit of the use of tyrosine kinase inhibitors (TKIs) in patients (pts) with METAstatic Soft Tissue SARComa (STS) in a Real-Life Setting: an anci...

Date 11 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Anti-Cancer Agents & Biologic Therapy
Soft Tissue Sarcomas
Sarcoma
Presenter Sophie Cousin
Citation Annals of Oncology (2017) 28 (suppl_5): v521-v538. 10.1093/annonc/mdx387
Authors S. Cousin1, M. Savina2, A. Le Cesne3, J. Blay4, I. Ray-Coquard5, O. Mir6, M. Toulmonde1, P. Terrier7, D. Ranchere-Vince8, P. Meeus9, E. Stoeckle10, C. Honore11, P. Sargos12, M.P. Sunyach13, C. Le Pechoux14, A. Giraud15, C. Bellera2, F. le loarer16, A. Italiano1
  • 1Medical Oncology, Institute Bergonié, 33076 - Bordeaux/FR
  • 2Department Of Epidemiology And Clinical Research, Institut Bergonié Régional Cancer Institute of Bordeaux, 33000 - Bordeaux/FR
  • 3Department Of Medical Oncology, Gustave Roussy Cancer Campus, 94805 - Villejuif/FR
  • 4Medical Oncology, Centre Leon Berard, 69008 - Lyon/FR
  • 5Medical Oncology, Léon Bérard Center, 69008 - Lyon/FR
  • 6Department Of Medical Oncology, Gustave Roussy Cancer Campus, 94800 - Villejuif/FR
  • 7Department Of Pathology, Institut Gustave Roussy, Villejuif/FR
  • 8Biopathology, Centre Leon Berard, Lyon/FR
  • 9Chirurgie, Centre Léon Bérard, 69008 - Lyon/FR
  • 10Surgery, Institute Bergonié, 33076 - Bordeaux/FR
  • 11Surgery, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 12Radiotherapy, Institute Bergonié, 33000 - bordeaux/FR
  • 13Radiotherapy, Centre Leon Berard, 69008 - lyon/FR
  • 14Radiation Oncology, Institut Gustave Roussy, Villejuif/FR
  • 15Clinical And Epidemiological Research Unit, Institute Bergonié, 33076 - Bordeaux/FR
  • 16Pathology, Institute Bergonié, 33000 - bordeaux/FR

Abstract

Background

Treatment options for pts with advanced STS are limited. STS, like other proliferating malignancies, are dependent on the formation of new blood vessels to support their growth, invasion and metastasis. Growth Modulation Index (GMI) has been demonstrated as a relevant endpoint to assess clinical in patients with advanced STS. There are no data related to GMI in STS patients treated with anti-VEGFR targeted therapy.

Methods

Pts with metastatic STSs diagnosed between 1990 and 2013 and documented in the prospectively maintained database of the French Sarcoma Group who have received at least one TKI during their treatment were analysed. GMI, defined as the ratio of the Time To Progression (TTP2) under the TKI/TTP under the previous line of treatment (TTP1) was calculated.

Results

209 pts (102 male) were included in this study. Median age was 50 (11-83). 234 lines of TKI were administrated. The drugs used were: Pazopanib (77, 33%), Sorafenib (70, 30%), Sunitinib (45, 19%), Regorafenib (30, 13%), Others (12, 5%). The most frequent histology subtypes were: leiomyosarcoma (64, 30.6%), undifferentiated sarcoma (28, 13.4%), synovialosarcoma (20, 9.6%), desmoplastic round cell tumor (14, 6.7%) and angiosarcoma (11, 5.3%). Median of previous lines was 2 (0 – 4). Median TTP under TKI was 4.1 months (0 – 131.1). GMI was available for 201 pts. Median GMI was 0.76 (0.02 - 12.49). GMI was ≥ 1 in 87 (41.6%) pts and ≥ 1.3 in 65 (31.1%) pts. 17 pts received 2 consecutive lines of TKI. For these pts, median GMI (TTP under TKI2/TTP under TKI1) was 1 (0.12 – 8.77). Seven (41.2%) had a GMI ≥ 1.3.

Conclusions

Targeting VEGFR was associated with significant clinical benefit (GMI ≥ 1.3) in about one third of STS pts. Up to 41% of patients progressing on a TKI experienced clinical benefit with another TKI suggesting the lack of absolute cross-resistance between TKI.

Clinical trial identification

Legal entity responsible for the study

French Sarcoma Group

Funding

None

Disclosure

All authors have declared no conflicts of interest.